Want to see OBIO full AI Analyst Report?

Orchestra BioMed Holdings (OBIO) Price & Analysis

111 Followers

OBIO Stock Chart & Stats

$4.58

-$0.06(-1.07%)

At close: Jan 08 4:00 PM EST

$4.58

-$0.06(-1.07%)

Day’s Range― - ―

52-Week Range$2.20 - $5.42

Previous CloseN/A

Volume15.92K

Average Volume (3M)418.70K

Market Cap

$234.73M

Enterprise Value$237.01M

Total Cash (Recent Filing)$94.40M

Total Debt (Recent Filing)$33.63M

Price to Earnings (P/E)―

Beta1.87

Next Earnings

Aug 18, 2026

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.42

Shares Outstanding59,880,714

10 Day Avg. Volume798,680

30 Day Avg. Volume418,705

Financial Highlights & Ratios

PEG Ratio0.18

Price to Book (P/B)2.51

Price to Sales (P/S)4.76

P/FCF Ratio-3.22

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue7.24

Enterprise Value/Gross Profit7.30

Enterprise Value/Ebitda-4.50

Forecast

1Y Price Target

$11.40

Price Target Upside148.91% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.56

Revenue Forecast (FY)$545.43K

Bulls Say, Bears Say

Bulls Say

Low Leverage / Balance-sheet CushionThe company's minimal debt (debt-to-equity ~0.04) provides durable financial flexibility for a development-stage biotech. Low leverage reduces near-term refinancing and interest obligations, allowing cash to be allocated to clinical programs and partnership development rather than debt service.

Very High Gross MarginsDevice-based revenues with ~99% gross margins indicate strong product-level economics and scalability once fixed R&D and G&A absorption improves. High unit margins are a structural advantage for long-term profitability potential if commercialization and volume ramp are achieved.

Governance & Incentive AlignmentRecent shareholder approval of directors and a 2026 equity incentive plan supports management continuity and talent retention. Stable governance and incentive structures help attract strategic partners and experienced executives needed to advance clinical programs and commercialization over the medium term.

Bears Say

Heavy Cash BurnSustained negative operating and free cash flow (~-$54–55M TTM) represents a structural funding challenge. Persistent cash burn forces reliance on external financing or partnerships, increasing dilution or negotiation pressure and constraining the firm's ability to fund multiple clinical programs concurrently.

Persistent Operating Losses And Negative ReturnsMaterial and recurring net losses (~-$55M TTM) producing a strongly negative ROE indicate ongoing destruction of shareholder value. Without sustained operating leverage or meaningful revenue diversification, losses undermine long-term capital formation and partner confidence needed for commercialization.

Revenue Volatility And DeclineHighly volatile revenue—large YoY declines—reduces predictability of cash flow and runway planning. Dependence on lumpy revenues or non-recurring events makes it harder to demonstrate sustained commercial traction, complicating investment decisions and long-term operating scale-up.

Orchestra BioMed Holdings News

Orchestra BioMed joins Russell 3000, Russell 2000 Indexes

Orchestra BioMed (OBIO) announced that it has joined the broad-market Russell 3000 Index and the small-cap Russell 2000...

12d ago

OBIO

Orchestra BioMed Shareholders Approve Directors and Incentive Plan

Orchestra BioMed Holdings ( ($OBIO) ) has issued an announcement. On June 23, 2026, Orchestra BioMed Holdings, Inc....

18d ago

OBIO

Orchestra BioMed price target lowered to $10 from $12 at B. Riley

B. Riley lowered the firm’s price target on Orchestra BioMed (OBIO) to $10 from $12 and keeps a...

2M ago

OBIO

Orchestra BioMed price target raised to $13 from $12 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Orchestra BioMed (OBIO) to $13 from $12 and...

2M ago

OBIO

Orchestra BioMed reports Q1 EPS (33c), consensus (44c)

Reports Q1 revenue $110,000, consensus $160,830. David Hochman, chairman and CEO of Orchestra BioMed (OBIO) stated, “We continued...

2M ago

OBIO

Orchestra BioMed gives clinical, regulatory update on BACKBEAT trial timeline

Orchestra BioMed (OBIO) announced an update to the overall clinical and regulatory timeline for the BACKBEAT Trial evaluating...

2M ago

MDT

OBIO

Orchestra BioMed receives $15M payment from Ligand

Orchestra BioMed (OBIO) announced the receipt of a $15M payment from Ligand (LGND) pursuant to the previously disclosed...

2M ago

LGND

OBIO

Orchestra granted additional breakthrough device designation for AVIM therapy

Orchestra BioMed (OBIO) announced that the FDA has granted a second breakthrough device designation, or BDD, for AVIM...

2M ago

MDT

OBIO

Orchestra BioMed: Accelerating Pivotal Trials and Strengthened Liquidity Support Buy Rating and Long‑Term Growth Outlook

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Orchestra BioMed Holdings,...

4M ago

OBIO

Midday Fly By: Dick’s Sporting, Dollar General report quarterly beats

The major averages were broadly lower near noon as market volatility continues amid the war in Iran and...

4M ago

Orchestra BioMed reports FY25 EPS ($1.11), consensus ($1.74)

Reports FY25 revenue $33.482M, consensus $3.47M. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed (OBIO) stated,...

4M ago

OBIO

Orchestra BioMed: Undervalued Cardiovascular Innovator Poised for Multi‑Year Catalyst Cycle

TD Cowen analyst Josh Jennings reiterated a Buy rating on Orchestra BioMed Holdings today and set a price...

4M ago

OBIO

Orchestra BioMed management to meet with B. Riley

Meeting to be held in Los Angeles on March 16 hosted by B. Riley. Published first on TheFly...

4M ago

OBIO

Orchestra BioMed Adopts 2026 Performance-Driven Executive Compensation Plan

Orchestra BioMed Holdings ( ($OBIO) ) has issued an announcement. On February 12, 2026, Orchestra BioMed Holdings, Inc.’s...

5M ago

OBIO

OBIO FAQ

What was Orchestra Biomed Holdings, Inc.’s price range in the past 12 months?

Orchestra Biomed Holdings, Inc. lowest stock price was $2.20 and its highest was $5.42 in the past 12 months.

What is Orchestra Biomed Holdings, Inc.’s market cap?

Orchestra Biomed Holdings, Inc.’s market cap is $234.73M.

When is Orchestra Biomed Holdings, Inc.’s upcoming earnings report date?

Orchestra Biomed Holdings, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 38 days.

How were Orchestra Biomed Holdings, Inc.’s earnings last quarter?

Orchestra Biomed Holdings, Inc. released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.1.

Is Orchestra Biomed Holdings, Inc. overvalued?

According to Wall Street analysts Orchestra Biomed Holdings, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Orchestra Biomed Holdings, Inc. pay dividends?

Orchestra Biomed Holdings, Inc. does not currently pay dividends.

What is Orchestra Biomed Holdings, Inc.’s EPS estimate?

Orchestra Biomed Holdings, Inc.’s EPS estimate is -0.39.

How many shares outstanding does Orchestra Biomed Holdings, Inc. have?

Orchestra Biomed Holdings, Inc. has 59,880,714 shares outstanding.

What happened to Orchestra Biomed Holdings, Inc.’s price movement after its last earnings report?

Orchestra Biomed Holdings, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Orchestra Biomed Holdings, Inc.?

Currently, no hedge funds are holding shares in OBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Orchestra BioMed Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

-137.99%

Trailing 12-Months

Asset Growth

70.46%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Orchestra Biomed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Orchestra BioMed Holdings (OBIO) Earnings & Revenues

Historic Earnings Reports

OBIO Stock 12 Month Forecast

Average Price Target

$11.40

▲(148.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","4.75":"$4.75","8.5":"$8.5","12.25":"$12.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.75,8.5,12.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.3,5.123076923076923,5.946153846153846,6.769230769230769,7.592307692307692,8.415384615384614,9.23846153846154,10.061538461538461,10.884615384615383,11.707692307692307,12.53076923076923,13.353846153846153,14.176923076923078,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.3,4.846153846153846,5.392307692307693,5.938461538461539,6.484615384615385,7.030769230769231,7.576923076923077,8.123076923076923,8.669230769230769,9.215384615384615,9.76153846153846,10.307692307692308,10.853846153846154,{"y":11.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.3,4.661538461538461,5.023076923076923,5.384615384615384,5.746153846153846,6.107692307692307,6.469230769230769,6.8307692307692305,7.192307692307692,7.553846153846154,7.915384615384616,8.276923076923076,8.638461538461538,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.34,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.97,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.83,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >